Meeting
2023 ASCO Quality Care Symposium
Learning about and living with toxicity: A qualitative study of patients receiving immune checkpoint inhibitors for melanoma or lung cancer and their caregivers.
Authors
Ayo Samuel Falade
Mass General Brigham, Salem, MA
Ayo Samuel Falade, Kelly Hsu, Riley Fadden, Kerry Lynn Reynolds, Jennifer S. Temel, Joseph A. Greer, Laura A Petrillo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care
Sub Track
Toxicity Prevention, Assessment, and Management
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 297)
DOI
10.1200/OP.2023.19.11_suppl.297
Abstract #
297
Poster Bd #
K8
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Estimating treatment-free survival (TFS) over extended follow-up in patients (pts) with advanced melanoma (MEL) treated with immune-checkpoint inhibitors (ICIs): Five-year follow-up of CheckMate 067.
First Author: Meredith M. Regan
Poster
2024 ASCO Annual Meeting
Organ-specific immune-related adverse events and survival in patients with cancer with immune checkpoint inhibitors.
First Author: Jun Wang
Poster
2023 ASCO Annual Meeting
Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer.
First Author: Jarushka Naidoo
Poster
2023 ASCO Genitourinary Cancers Symposium
Clinical outcomes of patients with metastatic renal cell carcinoma who discontinued nivolumab +/- ipilimumab therapy electively or due to toxicity.
First Author: Jessica Heejin Yoo